- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Spesolimab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Interventions
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment, HS low dose treatment, HS medium dose treatment, HS high dose treatment
- Drug
- Lead sponsor
- InflaRx GmbH
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Fountain Valley, California • North Miami Beach, Florida • Tampa, Florida + 6 more
- Conditions
- Venous Thromboembolism
- Interventions
- Atorvastatin, Anticoagulation Therapy
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio